Section 1 of 6
Terms and abbreviations
1 evidence topic · 0 sources
| Abbreviation | Term |
|---|---|
| ACTH | Adrenocorticotropic hormone |
| ADLT | Advanced diagnostic laboratory test |
| ADR | Adverse drug reaction |
| AE | Adverse event |
| AESI | Adverse event of special interest |
| AGV | Annualized growth velocity |
| AHFS | American Hospital Formulary Service |
| ALK | Anaplastic lymphoma kinase |
| ALT | Alanine aminotransferase |
| ANOVA | Analysis of variance |
| APC | Annual percent change |
| ARAF | A-Raf proto-oncogene, serine/threonine kinase |
| ASHP | American Society of Health-System Pharmacists |
| AST | Aspartate aminotransferase |
| ATC | Anatomical Therapeutic Chemical classification |
| AUC | Area under the concentration-time curve |
| BCRP | Breast cancer resistance protein |
| BCVA | Best-corrected visual acuity |
| BFS | Blindness-free survival |
| BL | Baseline |
| BOR | Best overall response |
| BRAF | B-Raf proto-oncogene, serine/threonine kinase |
| BRAFi | BRAF inhibitor |
| BSA | Body surface area |
| BTG | Brain Tumour Group |
| CAD | Canadian dollars |
| CAP | College of American Pathologists |
| CBR | Clinical benefit rate |
| CBTRUS | Central Brain Tumor Registry of the United States |
| CCLG | Children's Cancer and Leukaemia Group |
| CDA-AMC | Canada's Drug Agency (formerly CADTH) |
| CDKN2A | Cyclin-dependent kinase inhibitor 2A |
| CFR | Code of Federal Regulations |
| CHG | Chiasmatic-hypothalamic glioma |
| CHMP | Committee for Medicinal Products for Human Use |
| CI | Confidence interval |
| CL/F | Apparent oral clearance |
| CLIA | Clinical Laboratory Improvement Amendments |
| CMA | Conditional marketing authorisation |
| Cmax | Maximum plasma concentration |
| Cmin | Minimum plasma concentration |
| CMS | Centers for Medicare and Medicaid Services |
| CNS | Central nervous system |
| CNS5 | Fifth edition of the WHO Classification of Tumors of the Central Nervous System |
| COG | Children's Oncology Group |
| CPK | Creatine phosphokinase |
| CR | Complete response |
| CRAF | C-Raf proto-oncogene, serine/threonine kinase (RAF1) |
| CTCAE | Common Terminology Criteria for Adverse Events |
| CV | Carboplatin and vincristine |
| CVFQ | Children's Visual Function Questionnaire |
| CYP | Cytochrome P450 |
| D+T | Dabrafenib plus trametinib |
| Dab-Tram | Dabrafenib plus trametinib |
| DDI | Drug-drug interaction |
| DLT | Dose-limiting toxicity |
| DMC | Data monitoring committee |
| DNA | Deoxyribonucleic acid |
| DOR | Duration of response |
| DOT | Duration of treatment |
| DS | Diencephalic syndrome |
| DT | Distress Thermometer |
| EC | European Commission |
| ECHO | Echocardiogram |
| EF | Ejection fraction |
| EFS | Event-free survival |
| eGFR | Estimated glomerular filtration rate |
| EHR | Electronic health record |
| EMA | European Medicines Agency |
| EORTC | European Organisation for Research and Treatment of Cancer |
| ER | Emergency room |
| ERK | Extracellular signal-regulated kinase |
| ESS | Effective sample size |
| EU | European Union |
| FDA | US Food and Drug Administration |
| FDCA | Federal Food, Drug, and Cosmetic Act |
| FEP | Federal Employee Program |
| FFPE | Formalin-fixed, paraffin-embedded |
| FGFR | Fibroblast growth factor receptor |
| FISH | Fluorescence in situ hybridization |
| FLAIR | Fluid-attenuated inversion recovery |
| FT | Financial toxicity |
| G-BA | Gemeinsamer Bundesausschuss (Federal Joint Committee, Germany) |
| GBG | Gliome de bas grade (low-grade glioma) |
| GG | Ganglioglioma |
| GH | Growth hormone |
| GI | Gastrointestinal |
| GKV | Gesetzliche Krankenversicherung (statutory health insurance, Germany) |
| GnRH | Gonadotropin-releasing hormone |
| GTR | Gross total resection |
| GV | Growth velocity |
| HAS | Haute Autorité de santé (French National Authority for Health) |
| HGG | High-grade glioma |
| HI | Hepatic impairment |
| HR | Hazard ratio |
| HRQoL | Health-related quality of life |
| HRU | Healthcare resource utilization |
| HSR | Hypersensitivity reaction |
| HTA | Health technology assessment |
| HTACG | Member State Coordination Group on Health Technology Assessment |
| HTD | Health technology developer |
| IC50 | Half-maximal inhibitory concentration |
| ICD-10 | International Classification of Diseases, Tenth Revision |
| ICD-O-3 | International Classification of Diseases for Oncology, Third Edition |
| ICER | Incremental cost-effectiveness ratio; Institute for Clinical and Economic Review |
| ICH | Intracranial hemorrhage |
| IDH | Isocitrate dehydrogenase |
| IHC | Immunohistochemistry |
| IND | Investigational new drug application |
| INV | Investigator |
| IQ | Intelligence quotient |
| IQR | Interquartile range |
| IQWiG | Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (Institute for Quality and Efficiency in Health Care, Germany) |
| IRC | Independent review committee |
| ITDs | Internal tandem duplications |
| ITH | Intratumoral hemorrhage |
| ITT | Intention to treat |
| IV | Intravenous |
| JCA | Joint Clinical Assessment |
| LDH | Lactate dehydrogenase |
| LGG | Low-grade glioma |
| LOGGIC | Low-Grade Glioma in Children consortium (SIOPe Brain Tumour Group) |
| logMAR | Logarithm of the minimum angle of resolution |
| LTFU | Long-term follow-up |
| MAH | Marketing authorisation holder |
| MAIC | Matching-adjusted indirect comparison |
| MAPK | Mitogen-activated protein kinase |
| MAPKi | MAPK pathway inhibitor |
| MATE | Multidrug and toxin extrusion protein |
| MDRD | Modification of Diet in Renal Disease |
| MEK | Mitogen-activated protein kinase kinase |
| MEKi | MEK inhibitor |
| MHLW | Ministry of Health, Labour and Welfare (Japan) |
| MR | Minor response |
| MRI | Magnetic resonance imaging |
| MTD | Maximum tolerated dose |
| MYBL | MYB proto-oncogene like |
| NA | Not applicable |
| NCCN | National Comprehensive Cancer Network |
| NDA | New drug application |
| NDC | National Drug Code |
| NE | Not evaluable |
| NF-1 | Neurofibromatosis type 1 |
| NF-2 | Neurofibromatosis type 2 |
| NF1 | Neurofibromatosis type 1 (gene: neurofibromin 1) |
| NF1-LOF | Neurofibromatosis type 1 loss of function |
| NGS | Next-generation sequencing |
| NICE | National Institute for Health and Care Excellence |
| NOPHO | Nordic Society of Paediatric Haematology and Oncology |
| NR | Not reached |
| NTRK | Neurotrophic tyrosine receptor kinase |
| OAT | Organic anion transporter |
| OATP | Organic anion-transporting polypeptide |
| OCT | Organic cation transporter |
| OIS | Oncogene-induced senescence |
| OPG | Optic pathway glioma |
| OR | Odds ratio |
| ORR | Overall (objective) response rate |
| OS | Overall survival |
| P-gp | P-glycoprotein |
| PA | Pilocytic astrocytoma |
| PBPK | Physiologically based pharmacokinetic |
| PBTC | Pediatric Brain Tumor Consortium |
| PBTS | Pediatric brain tumor survivors |
| PD | Progressive disease; pharmacodynamics (in PK/PD) |
| PedsQL | Pediatric Quality of Life Inventory |
| pERK | Phosphorylated extracellular signal-regulated kinase |
| PFS | Progression-free survival |
| PICO | Population, intervention, comparator, outcome |
| PK | Pharmacokinetics |
| PLGA | Pediatric low-grade astrocytoma |
| PLGG | Pediatric low-grade glioma |
| pLGG | Pediatric low-grade glioma |
| PMR | Postmarketing requirement |
| PN | Plexiform neurofibroma |
| popPK | Population pharmacokinetics |
| PPK | Population pharmacokinetics |
| PR | Partial response |
| PRO | Patient-reported outcome |
| PROMIS | Patient-Reported Outcomes Measurement Information System |
| PSUR | Periodic safety update report |
| pU | Pharmazeutischer Unternehmer (pharmaceutical company) |
| PXA | Pleomorphic xanthoastrocytoma |
| Q2D | Once every other day |
| QALY | Quality-adjusted life-year |
| QOL | Quality of life |
| QoL | Quality of life |
| QT | QT interval (electrocardiogram) |
| QW | Once weekly |
| RAF | Rapidly accelerated fibrosarcoma kinase |
| RANO | Response Assessment in Neuro-Oncology |
| RANO-HGG | Response Assessment in Neuro-Oncology criteria for high-grade glioma |
| RANO-LGG | Response Assessment in Neuro-Oncology criteria for low-grade glioma |
| RAPNO | Response Assessment in Pediatric Neuro-Oncology |
| RAPNO-LGG | Response Assessment in Pediatric Neuro-Oncology criteria for low-grade glioma |
| RAS | Rat sarcoma virus GTPase |
| RCT | Randomized controlled trial |
| RECIST | Response Evaluation Criteria in Solid Tumors |
| REMS | Risk Evaluation and Mitigation Strategy |
| RI | Renal impairment |
| RNA | Ribonucleic acid |
| RP2D | Recommended phase 2 dose |
| RR | Relative risk; rebound regrowth |
| RS | Retrospective study |
| RT | Radiotherapy |
| SAE | Serious adverse event |
| SASP | Senescence-associated secretory phenotype |
| SD | Stable disease; standard deviation |
| SEER | Surveillance, Epidemiology, and End Results |
| SES | Socioeconomic status |
| SIOP | International Society of Paediatric Oncology |
| SIOP-LGG | International Society of Paediatric Oncology Low Grade Glioma study |
| SIOPE | SIOP Europe (European Society for Paediatric Oncology) |
| SIOPe | SIOP Europe (European Society for Paediatric Oncology) |
| SmPC | Summary of product characteristics |
| sNDA | Supplemental new drug application |
| SNV | Single nucleotide variant |
| SOB | Specific obligation |
| SOC | Standard of care |
| SoC | Standard of care |
| SPF | Sun protection factor |
| Sub-TITE | Subgroup-specific time-to-event continual reassessment design |
| TAT | Turnaround time |
| TEAE | Treatment-emergent adverse event |
| TFI | Treatment-free interval |
| Tmax | Time to maximum plasma concentration |
| TPCV | Thioguanine, procarbazine, lomustine, and vincristine |
| TRAE | Treatment-related adverse event |
| TTNT | Time to next treatment |
| TTO | Time to onset |
| TTR | Time to response |
| UK | United Kingdom |
| ULN | Upper limit of normal |
| US | United States |
| USD | United States dollars |
| USPI | US Prescribing Information |
| V/C | Vincristine and carboplatin |
| VA | Visual acuity |
| VABS | Vineland Adaptive Behavior Scales |
| VBL | Vinblastine |
| VC | Vincristine and carboplatin |
| VCE | Vincristine, carboplatin, and etoposide |
| VF | Visual field |
| VI | Visual impairment |
| VP | Visual pathway |
| WAC | Wholesale acquisition cost |
| WG | Working group |
| WHO | World Health Organization |
| WT | Wild-type |